PAVmed Inc.

PAVM

US70387R4039

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 15:17:25 02/07/2024 BST			5-day change	1st Jan Change
0.739 ^USD	-3.27%		+3.24%	-81.43%

01:55pm	Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	CI
06-20	Transcript : PAVmed Inc. - Shareholder/Analyst Call

PAVmed Inc. Announces Executive Resignations

February 16, 2018 at 09:31 pm

On February 12, 2018, each of Ira S. Greenspan and Joshua R. Lamstein advised the board of directors of PAVmed Inc. that he was resigning as a member of the Board, effective immediately.

Latest news about PAVmed Inc.

Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	12:55pm	CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call	06-20
Transcript : PAVmed Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Pavmed Inc. Appoints Dennis Matheis to Board of Directors	05-07	CI
Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024	03-27
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	03-21	CI
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12-12	CI
Transcript : PAVmed Inc., Q3 2023 Earnings Call, Nov 15, 2023	11-15
PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection	07/09/23	CI
Transcript : PAVmed Inc., Q2 2023 Earnings Call, Aug 16, 2023	16/08/23
North American Morning Briefing : Stock Futures -2-	16/08/23	DJ
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
PAVmed Secures Extension to Regain Compliance With Nasdaq Listing Rules	29/06/23	MT
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell Microcap Growth Index	23/06/23	CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell Microcap Index	23/06/23	CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 3000E Growth Index	23/06/23	CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 3000E Index	23/06/23	CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call	21/06/23
Transcript : PAVmed Inc., Q1 2023 Earnings Call, May 17, 2023	17/05/23
North American Morning Briefing : Debt-Ceiling -2-	17/05/23	DJ
PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call	31/03/23

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.

Sector

Advanced Medical Equipment & Technology

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PAVmed Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.764 USD

Average target price

11.67 USD

Spread / Average Target

+1,427.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PAVMED INC.	-81.43%	7.21M
THERMO FISHER SCIENTIFIC	+1.52%	207B
DANAHER CORPORATION	+4.31%	181B
INTUITIVE SURGICAL, INC.	+28.71%	155B
BOSTON SCIENTIFIC CORPORATION	+31.73%	112B
SIEMENS HEALTHINEERS AG	+1.75%	64.42B
EDWARDS LIFESCIENCES CORPORATION	+18.86%	54.38B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.92%	47.43B
AGILENT TECHNOLOGIES, INC.	-8.26%	37.17B
GE HEALTHCARE TECHNOLOGIES INC.	-1.32%	34.81B

Other Advanced Medical Equipment & Technology

PAVmed Inc.

Equities

PAVM

US70387R4039

Advanced Medical Equipment & Technology

PAVmed Inc. Announces Executive Resignations

Latest news about PAVmed Inc.

Chart PAVmed Inc.

Company Profile

Income Statement Evolution

Ratings for PAVmed Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology